This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 1:52 PM CDT 4 min read

HighVista Strategies reported a merchantability of 238,243 shares of Viridian Therapeutics (NASDAQ:VRDN) successful its May 15, 2026, SEC filing, an estimated $7.08 cardinal commercialized based connected quarterly mean pricing.

What happened

According to a SEC filing dated May 15, 2026, HighVista Strategies reduced its involvement successful Viridian Therapeutics (NASDAQ:VRDN) by 238,243 shares during the archetypal quarter. The estimated worth of shares sold was astir $7.08 million, based connected the period's mean closing price. After accounting for banal terms movements, the quarter-end worth of the presumption declined by $8.97 million.

What other to cognize

Top holdings aft this filing:
- NYSEMKT:DBC: $30.61 cardinal (8.5% of AUM)
- NASDAQ:ABVX: $12.61 cardinal (3.5% of AUM)
- NASDAQ:PRAX: $8.48 cardinal (2.3% of AUM)
- NASDAQ:COGT: $7.58 cardinal (2.1% of AUM)
- NASDAQ:SYRE: $7.38 cardinal (2.0% of AUM)
As of May 14, 2026, shares of Viridian Therapeutics were priced astatine $17.43, up astir 35% implicit the past twelvemonth and good outperforming the S&P 500’s astir 25% gain.

Company overview

Metric

Value

Revenue (TTM)	$70.85 million
Net Income (TTM)	($342.6 million)
Price (as of marketplace adjacent 2026-05-14)	$17.43
One-Year Price Change	35%

Company snapshot

Viridian Therapeutics develops monoclonal antibody therapies, including VRDN-001, VRDN-002, and VRDN-003, chiefly targeting thyroid oculus illness (TED).
The steadfast operates a biotechnology concern exemplary focused connected research, objective development, and out-licensing oregon commercialization of proprietary therapeutic candidates.
It targets patients with superior diseases, with a superior absorption connected the healthcare and biotechnology sectors.

Viridian Therapeutics is simply a clinical-stage biotechnology institution specializing successful the improvement of antibody-based therapies for superior diseases, with an accent connected thyroid oculus disease. The institution leverages precocious monoclonal antibody exertion to code unmet aesculapian needs successful its people markets. Its strategical absorption connected innovative biologics positions it to vie successful the evolving scenery of specialty therapeutics.

What this transaction means for investors

Viridian has climbed astir 35% implicit the past year, and with a June 30 FDA determination looming for pb therapy veligrotug, immoderate investors whitethorn beryllium locking successful gains. The institution besides faced immoderate unit close astatine the extremity of past quarter, with shares falling implicit 30% aft the steadfast reported Phase 3 TED information that was positive, but fell abbreviated of expectations.

Still, the broader concern momentum continues to look solid. Earlier this month, Viridian said it is “launch-ready” up of veligrotug’s PDUFA day and highlighted affirmative Phase 3 information for subcutaneous campaigner elegrobart successful some progressive and chronic thyroid oculus disease. Management believes elegrobart could go the archetypal subcutaneous autoinjector attraction for TED, perchance giving the institution a differentiated commercialized space successful a marketplace presently dominated by infusions.

For semipermanent investors, the communicative present progressively hinges connected execution. A palmy FDA support and motorboat could materially reshape Viridian’s illustration from a development-stage biotech into a commercialized uncommon illness player.

Read Entire Article